Blog

Newmont Corporation (NEM) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NEM crossed above the 20-day moving average

A downtrend has been apparent in Inogen (INGN) lately with too much selling pressure. The stock has declined 10% over the past four weeks. However, given the fact that it is now in oversold

S&P Global (SPGI) has been beaten down lately with too much selling pressure. While the stock has lost 18.4% over the past four weeks, there is light at the end of the tunnel as it is now in

Paylocity (PCTY) has been on a downward spiral lately with significant selling pressure. After declining 24.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is

Middlefield Banc Corp. (MBCN) came out with quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.6 per share a year ago

A downtrend has been apparent in Workday (WDAY) lately with too much selling pressure. The stock has declined 25.7% over the past four weeks. However, given the fact that it is now in oversold

Iamgold (IAG) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, IAG crossed above the 20-day moving average, suggesting a

Chinese electric vehicle (EV) company NIO Inc. NIO is finally showing early signs of a long-awaited turnaround. After years of heavy losses, the company has guided for its first-ever quarterly

At a time when volatility strikes every second day, investors often rely on value investing rather than other options like growth or momentum. As soon as other investors start selling their stocks

For the quarter ended December 2025, Incyte (INCY) reported revenue of $1.51 billion, up 27.8% over the same period last year. EPS came in at $1.80, compared to $1.43 in the year-ago quarter.

The

Coca-Cola (KO) reported $11.82 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 2.4%. EPS of $0.58 for the same period compares to $0.55 a year ago.

For the quarter ended December 2025, CVS Health (CVS) reported revenue of $105.69 billion, up 8.2% over the same period last year. EPS came in at $1.09, compared to $1.19 in the year-ago quarter.

Aramark (ARMK) reported $4.83 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 6.1%. EPS of $0.51 for the same period compares to $0.51 a year ago.

Masco (MAS) reported $1.79 billion in revenue for the quarter ended December 2025, representing a year-over-year decline of 1.9%. EPS of $0.82 for the same period compares to $0.89 a year ago.

The

GCM Grosvenor Inc. (GCMG) reported $177.1 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 7.2%. EPS of $0.31 for the same period compares to $0.27 a

Astrazeneca (AZN) reported $15.5 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 4.1%. EPS of $1.06 for the same period compares to $2.10 a year

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts

Xylem (XYL) reported $2.4 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 6.3%. EPS of $1.42 for the same period compares to $1.18 a year ago.

The

For the quarter ended December 2025, Trimble Navigation (TRMB) reported revenue of $969.8 million, down 1.4% over the same period last year. EPS came in at $1.00, compared to $0.89 in the year-ago

Canaan (CAN) reported $196.27 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 121.1%. EPS of -$0.13 for the same period compares to -$0.33 a year

Marriott International (MAR) reported $6.69 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 4.1%. EPS of $2.58 for the same period compares to $2.45

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm

For the quarter ended December 2025, Zimmer Biomet (ZBH) reported revenue of $2.24 billion, up 10.9% over the same period last year. EPS came in at $2.42, compared to $2.31 in the year-ago quarter.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts